Q2 2022 InspireMD Inc Earnings Call
Good morning and welcome to the Inspire MD second quarter 2022 earnings call. At this time, all participants are in a listen only mode. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and zero. Please note this conference is being recorded.
I would now like to turn the conference over to Chuck Padala with LifeSci Advisors. Thank you. You may begin. Thank you, operator, and good morning, everyone. Thank you for joining us for the InspireMD second quarter 2022 financial results and corporate update conference call.
Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer, and Craig Schor, Chief Financial Officer.
During this call, management will be making forward-looking statements, not historical facts, and are based upon management's current expectations, beliefs, and projections, many of which, by their nature, are inherently uncertain.
They involve risks and uncertainties that may cause actual results to differ materially from those expressed in the forward-looking statements.
For more information about these risks, please refer to the risk factors described in Inspire MD's most recently filed periodic reports on Form 10-K and Form 10-Q filed with the U.S. Securities and Exchange Commission and Inspire MD's press release that accompanies this call. This particular case, particularly the cautionary statements stated.
The call contains time sensitive information that is accurate only as of today, August 9th, 2022.
except as required by law, InspireMD disclaims any obligations to publicly update or revise any information to reflect events or circumstances that occur after this call.
It is now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.
Thank you, Chuck, and thanks to everyone for joining our call this morning. During the second quarter, we continue to successfully execute on our mission to establish a new paradigm and standard of care for carotid artery disease treatment and stroke prevention.
The clear highlight was revenue totaling 1.5 million dollars, which represents a growth of nearly 48% as compared to the second quarter of last year.
This increase was driven by sales of our SeaGuard embolic prevention stent system.
When you ignore the strengthening of the U.S. dollar versus the euro of approximately 12%, our volume of units sold actually increased by 60%, which represented 2,602 units sold this quarter versus 1,623 in Q2 of 2021 and 1,910 units sold last quarter. We believe procedural volume is a more accurate indicator of market penetration as we currently share ASP revenue.
with distribution partners in the majority of our markets. This will certainly convert to a more robust top-line revenue as we move to a direct sales model in additional territories.
This market penetration is also reflective of our market share growth, which is now greater than 20% in over half of our markets, with some territories up to 60%. These measurements of business acceleration create tremendous momentum to the runway in front of us, and we continue to innovate and drive an endovascular shift to open surgery with the best performing carotid stent in the market.
The enabling features of the Seaguar platform through this novel design and proprietary micro-net mesh protection enable superior vascular patency compared with all other stent devices, including those with double layer design, as well as open surgery. With data out to five years reflecting consistent clinical outcomes, Seaguar continues to demonstrate unmatched short and long-term performance.
Our position is further bolstered with the growing transition from open surgery to endovascular standard of care when you consider less than 35% of carotid artery disease cases are currently treated through endovascular stenting procedures.
So there remains a significant percentage of carotid procedures that we believe can be converted from surgical to endovascular treatment. And with a large and growing body of clinical evidence demonstrating the superiority of C-Guard relative to competing therapies and stent alternatives, we look forward to leading this conversion. true.
Therefore, our strategy remains consistent, which is to focus on all specialists treating carotid artery disease.
to both convert open surgery as well as promote Seaguard as a first line endovascular device.
Turning our attention to other quarterly milestones.
Our presence at an important medical conference such as the Link Leipzig Interventional course, held this past June , remained an important opportunity for us to demonstrate SeaGuard in a live case format, as well as to meet KOLs influencing the market demand. We had a significant presence at Link this year, delivering four presentations in addition to a successful live case transmission featuring SeaGuard. The live case was performed by Dr. Andre Schmitt and Dr. Andreas Fischer.
at the University Hospital in Leipzig, Germany, performed on a 60-year-old asymptomatic male with progressive and calcified internal carotid stenosis.
The procedure was successful with excellent angiographic result. Importantly, the case gave treating vascular specialists from across Europe the opportunity to see firsthand not only SeaGuard's ease of use, but also the benefits of its superb conformability and micro-mesh protection innovation.
Just a few weeks ago, we announced that Dr. Juan Perotti has agreed to be a strategic advisor to the company. Dr. Perotti is a world-renowned endovascular pioneer, having performed the first-ever endovascular repair procedure in 1990 and the first carotid T-car procedure in 1994, the latter using reverse flow for cerebral protection.
Dr. Parodi's vast experience, unique perspectives, and guidance will be useful as we develop new solutions to advance stroke prevention and improve long-term patient outcomes.
The transition of carotid disease management from open surgery to endovascular standard of care is underway. And we believe having Dr. Parodi as an advisor and supporter of our technology speaks volumes about the benefits of SeaGuard relative to other stent platforms currently on the market.
Turning now to other developments.
In terms of our US IDE trial Sea Guardians, last quarter we indicated that we opened our first European trial site and enrollment has been accelerated.
We currently have 18 US sites enrolling patients with plans for four more and in Europe four sites are now enrolling and One more is expected to begin cases this month for a total of five
All 22 enrolling sites are building cases at an accelerating pace, which is encouraging.
Our current outlook remains consistent.
With enrollment completion by approximately Q1 2023.
Regarding Japan, our discussions with potential distribution partners interested in representing Sea Guard are ongoing and we're pleased to be seeing a very high level of interest.
An agreement once executed would complement the distribution agreement we have in China that was signed last year. Asia is a very important market for us and the existing standard of care for procedural intervention is predominantly endovascular focus and less surgically dominated than the US and certain European markets.
In February , we announced that C-Guard EPS would be included as a treatment option in the stenting arm of the CREST-2 trial, which is widely acknowledged as the most significant ongoing trial to scientifically investigate the optimal course of treatment to prevent strokes for asymptomatic patients with significant carotid disease. We view this as yet another important validation of our technology to be approved as an advanced STEM platform to participate in such an important market effort.
We've completed readiness for 20 sites to use SeaGuard, and we anticipate the first-patient treatments to be completed soon.
In terms of product platform.
The Seaguar EPS Stent platform remains the foundation of our business as the device drives patient outcomes beyond the selected delivery option.
To fully realize the full potential of SeaGuard, we've invested in two new delivery systems to drive utilization across the broadest vascular specialist community. We continue to advance development of our new trans-femoral delivery system SeaGuard Prime, which will be available in both standard and short shaft versions, compatible with the development of SwitchGuard, our TCAR accessory device.
In combinations, these will offer a transcarotid option to our portfolio, designed for those clinical needs and conversion of greater surgical procedures to the Seaguar EPS stent.
We continue to work tirelessly toward our goal of changing the paradigm of how carotid stenosis is managed. With Seaguard EPS, we believe we can offer the best patient outcomes and the broadest set of tools to unlock the tremendous potential of this rapidly evolving market segment. With that, I'll turn the call over to Craig for a review of our second quarter financials. Craig?
Thank you, Marvin. For the second quarter of 2022, revenue was $1,531,000 compared to $1,038,000 for the second quarter of 2021. This represents an increase of 47.6%. This increase was predominantly driven by a 47.8% increase in sales volume of CREPS to $1,505,000 for the second quarter of 2022.
from $1,019,000 for the same period one year ago.
This sales increase was mainly due to growth in existing and new markets as well as US sales related to stents used in the CDC Garnier US Food and Drug Administration clinical trial.
Gross profit for the second quarter of 2022 was $431,000 compared to a gross profit of $262,000 for the second quarter of 2021. This increase resulted from higher revenue and a reduction in miscellaneous expenses partially offset by a reduction in costs of goods sold due to an inventory adjustment that occurred during the three months ended June 30th, 2021, which did not occur during this current period.
Gross margin increased to 28.1% during the three months ended June 30th, 2022, from 25.2% during the three months ended June 30th, 2021.
Total operating expenses for the second quarter of 2022 were $5,112,000, an increase of $1,410,000 compared to $3,702,000 for the second quarter of 2021. This increase was primarily due to increases in expenses related to the commencement of the SeaGuardians FDA study, resume activities and trade shows, travel and share-based compensation.
Net loss for the second quarter of 2022 totaled $4,636,000, or $0.59 per basic and diluted share, compared to a net loss of $3,507,000, or $0.46 per basic and diluted share for the same period in 2021.
As of June 30th, 2022, cash, cash equivalents, and short-term bank deposits were $26.5 million compared to $34 million as of December 31st, 2021. Of note, there remains ongoing uncertainty of the changing regulatory environment in Europe specific to the timing of the renewal of certification to tell Seaguard under the new MDR rules structure. Our focus remains to work with the notified body to secure our renewal without delay.
I would like to now turn over the conference call to the operator for any questions.
Thank you. We will now begin the question and answer session. To join the question queue, you may press star then 1 on your telephone keypad. You will hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then 2. We will pause for a moment as callers join the queue.
The first question is from Ben Hayner from Alliance Global Partners. Please go ahead. Thank you.
Good morning guys, thanks for taking the questions and congrats on all the progress.
First off for me, just on the Q2 numbers, if I'm doing the math right, it looks like the ASP declined a little bit sequentially. I presume most of that is due to currency, which you called out a little bit. But was there also a geographic mix element in there? Can you also comment on how you guys are doing in the countries that you've gone direct thus far?
relative to the other distributor countries.
Hi Ben, it's Craig. Thanks for the question. So it was predominantly exchange, 12% impact, because if you look at the units that Marvin spoke about, we actually grew 60% and our revenue was only up 48%. There was a slight change in the mix, but it wasn't material.
So, I'll now turn it over to Marvin and he can give you an update on the direct sales. Yeah, Ben. Thanks. Thanks for the question. So right now we are direct in the UK and in France and we have plans to expand that. Direct model likely toward the end of the year beginning of next year. We haven't. Openly announced those territories yet as we're in the process of transitioning some of those with our distributor partners, but certainly more color will will come on those as we, as we get those buttoned up likely by next quarter.
Okay, got it. Can you, um...
maybe not repeat, but revisit the market share growth statistics that you mentioned earlier in the prepared remarks, the 20% to 60% growth you're seeing there. I was wondering if that's versus other carotid scent platforms or as a share of all carotid procedures. idolize the trades how you can get these companies to heat up businesses across as pulled out
Yeah, so when we calculate market share, we calculate it off of cast procedures. So, crowded stenting procedures versus competitors. Not open surgeries, and as we mentioned in more than 50% of our markets, we have over 20% share and in some cases up to 60%. So we. We certainly use this as a proxy and a guideline to market penetration. And, of course, expanding the overall cast market, converting surgeries.
to stenting is our equally important objective, but within the current CAF environment, we look at that as a growth goal commercially. So it's those two pillars transition more surgery to stenting and gain higher share percentages within the existing endovascular stenting segment. So that's a big marker for our success.
Okay, that makes sense, just to clarify in there. And then, it seems one of your competitors on the TCAR side of things is not going to pursue European regulatory clearance, and it looks like you guys may have the market to yourself with that style of procedure. Any thoughts that you guys have on that?
Yeah, we certainly acknowledge that within the European market, there is an ongoing need for considering TCAR as an alternative delivery option. In fact, many vascular surgeons use homemade kits and other things that they prefer, more of a direct access to the carotid. So we're certainly excited about serving that market with an alternative to our transfemoral system.
And I think the combination of those two things will continue to drive more stenting. We have a fairly high conversion rate now within vascular surgeons to even use our trans-femoral system. We guess that we're somewhere around 20% of the overall procedures by vascular surgeons are done trans-femorally, but we're excited about offering an option within the community for TCAR as well so that we can drive everyone toward a stenting solution. Of course with C-Guard is.
the right way to think about it.
Yeah, I think so. Ben, we, we've moved through the, the engineering and V and V phase and development part of the process and we're now on to the regulatory pathways. So assuming things remain on track there. I think our, our timing relative to what we've spoken about before seems to be pretty consistent, but we're now into the into the regulatory approval phase, which certainly has some variability.
And lastly, for me, I press two congrats to 20 sites. That's maybe more than I might have expected. Do you know how many patients in the CASR remain to be enrolled? How many of you're on that board of directors are here?
And it seems like you might expect an decent percentage of those if it's 20 sites.
Yeah, it's a good question, Ben. I don't have a firm number on the patient enrollment overall. We know the stenting arm is a bit behind the other options, but we look forward to beginning the process of making Seaguard available, like you said, to those 20 sites. We actually started with participants in the Seaguardians trial. There were also Crest 2 enrollers, easiest path to follow. And then we've actually taken some Crest 2 sites.
that weren't in Sea Guardians and converted those back as well. So it's been a good opportunity to have a discussion on SeaGuard for both of those options available to patients.
I think that's all I had gentlemen. Thanks for the update and taking the questions and congrats on all the progress.
Thanks, Ben. We appreciate the coverage.
This concludes the question and answer session. I would like to turn the conference back over to Marvin's last minute for any closing remarks.
Thank you operator. I'd like to thank everyone for taking the call today and your ongoing support. We're extremely proud of the progress from this quarter and through the 1st, half of the year and look forward to the next quarterly update in November and our continuing progress.
This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.
The that.
you
couring and the second court 20 20, two ING call only after the pres opportunity. questionions in the question Star: one under on ance the conferens call oper by pro AR and conference COUR the conference over with five may in operat courning every one ining the second courarter 20 20, two resu court feren call Y office COUR call be COUR state's and COUR expectation projion certain that resu thir ly those and COUR sent promission KS five court 4, 10 form the cur mission and pres any call the court Ed the call promission two thousand 20, two COUR by law five the legation pro D Form five remissation sent after call call law and thanks one for joining our call the COUR ING the second courarter we ue to success fully execute on our mission to ABL new par standard of care for corrted ory disease treatment and prevention. The courar high light was revenue tot one point five million dollars which representcent of nearly 48% as compared to the second courarter of last year. Increase was by sils of C guard prevention sent system, the ING the's doll vers the U proxim. We percent actually increase by 60%, which represent 20, six hundred two UN this courarter for sixteen hundred 20 Y two of Y 20, one and 19 hundred 10 UN. Last courarter we believe proced lawu as the more actcur indicc of market ation and we courren revenue with disribution partners in the jory of markets certainly con to more line revenue ANDAs we move to a direct alil model and additional terriatories courket tration also reflected of our market COUR, which 20% and over half of our marke with some atory up to 60%. The bus six celeration mend ment to the run way fron and we continue to and D vascular open surgery with the form COR T sent and the market the abable features of C guard platform, the prior my proteion and abable superi vascular paten C compared all sent ves, including those with public as well surgery with out to five year reflecting consisting clinical outcomes. Guard continue to demon TR, courort and long term formments. Position for withthe couring transition from open surgery end vascular standard of care when con Thirty 5% of cted arory disease cases courrent, tre and Vascular senting procedures remain the significant percented ofcorrt procedures we believe. converteded from surge to end vcular treatment and with the couring partty of clinical evid demonstrtring the superi ory of C guard re to peting sent ter.ed we for to leading con version for strateed remain which to cus on all special ING cross or ory DIS both conver open surgery as well C guard as the first line and Vascular device. Turn our ention to other courarterly sent presence. Important medical conference, the L vention COUR LD J remain important opportunity for us demonstrtr C Guard and the five case form as well to in the market mand we had significant presence this year. Deliver four presentation in addition to the successful case Trans mission Fe C guard the casees Form by DR under and DR F and the vers jy Form on the 60 year aIl gress coun five and intern Al cted the proced with successful with ll AP resu important the case tre ING vascular special across year opportunity to C first not only C guard benefits Form ability and my proteion and ationion. We the DR one pro Y has to be a strategic five to the companyy DR pro Y end vascular year proform the first and Vascular procedure and 19 nin and the first corrt CAR proced and nine niny four the ING for proteion pro Ty V experi pected and GU will be use. We develop sol Ion to V prevention and prove long ter patation outcom the transition ofcorcted disease manage ment for surgery to end vascular standard of COUR under way and we believe DR pro Y vis and courtter of our technoy about the benefits of C guard rel to under sent platforms courrently on market turning out other develop turnms's trial C guard last courarter icated to ened our first European trial C and roll ment has been excelated. We rent have eighteteen in rolling with planans for Form more and four now rolling and one more expected to beg cases. This to five 20, two rolling C? Ing cases in in excelerating case which courion courrent out look, remain consistent with in rolling comtion by proxim ly one 20, 20 Y guard discussions with the tental disribution partners and re present C guard ongoing and ase to be high leve of interest ree ment execed with con? ment the disribution agreement we have the ED last year important market for us and the existing standard of care pro in vention ment and Vascular cus and surg? ly ominated in the and Europe markets. And C guard's would be included as three ment option in the senting AR of the two trial noledars, the most significant ongoing trial to V? Ate the optim court treatment to vent for a to ence with significant corrted disease. We other important idation of our techno to be pro as an vance platform to particippate important market after Ted ING for 20 C C Guard and we icippate the first patation treatment to be completed and ter? pri platform. The C guard's sent platform remain the found ation of our bus as the Vice RI patation outcomes be on the selected delivery option fully the 4? tention of C? Guard. We invest two delivery system to dire ation proross the pro est vcular special community. We continue to V development of our new Trans former delivery system C guard pri which will be ailable standard and courort surgions comp with the development of guard GU cess ory device comination. The off? Er Trans corrt option to our COUR for for those clinical conversion of COUR? G procedures to thec guard sent. Continue to COUR our changing the par COR? T to man guard's. We believe we offer the ation outcom and the to law the mend tention of the reapidly of all ING market sentment turn call over to for re our second courarter Act for the second courarter of two thousand 20, two revenue one million five hundred thirtyy one thousand dollars. Compared one million Thirty eight thousand dollars for the second courarter of two thousand 20 1, the represent increase the Forty seven point 6%. The increase fortyy 8% increase Sal law: P one million five hundred five thousand dollars for the second courarter two thousand Y 2, one million 19 thousand dollars for the one year crease ue existing new marke related sent the guard's TR clinical trial COUR pro for the second courarter two thousand 20 2, four hundred Thirty one thousand dollars compared to pro one 60, two thousand dollars for the second courarter two thousand 20, one the increase from revenue and re ction the sentenses part re Ion COUR ue were COUR the 3, one and Thirty two thousand 20, one which not COUR courren COUR inase the 20 point 1%. The three Mon Thirty two thousand Y two 20, five point 2% uring the 3, one Thirty two thousand 20, one opering sentens for the second courarter two thousand 20 2, five million one hundred thousand dollars and increase the one million four hundred thousand dollars compared three million seven hundred two thousand dollars for the second courarter two thousand 20, one the increase ly ue inase an sentens reated to the commend ment of thec guard resu tivities TRI conenscation law for the second courarter two thousand 20 2, four million 6, Thirty six thousand dollars 60, nine sent ase ated compared to law three million five hundred seven thousand dollars. Forty six sent ase for the two thousand 20, one Thirty two thousand 20, two COUR ort the which 20, six point five milliondollars compared the Thirty four million dollars of the the thir two thousand 20, one on going certain of the changing were the to the time the new ation C guard under the new and the UL remain to the five C over the conference COUR to the oper questionions. Thank in the question sion join the question. May Star one on ING ING presing case ase question Star two ment call ING question line COUR partners. Cour question ions ress progress. The question COUR also there. The com GU the direct of the other disri's's for change percent. You look at the UN COUR Act COUR 60%. Our revenue was 48%, the. The change was date on the dire. Thank for the question. Now we direct in the U, K and FR and we have land to direct model likely to the end the year, begining next year. We have open those riator as were in the process of transitioning some of those with our disri partners but certainly courll come on those as we as we get those likely by next courarter the ket Ion the 20 per 6% COUR C there and COUR sent courars, CRT procedures. Yes, when we counculate market we we counculated C procedures C? T senting procedures Peters, open surgeries as we Ion and more 60% of our market we have over 20% and cases up the 60 cent. So we we certainly use as the prox in GU line two to mar tration and court exexpending the over all C mar conver surgeries two sentending important of jected within the courren and ment we we look that courth erci.ion So of those two illars transition COUR surgery sentending and re percentag within the existing vascular senting sentgment So that that the mar cess courar Y on AR ator courar GU the market with that procedure GU have certainly that within the Europe market and ongoing four consent Guard and tered delivery option fact vascular GE use and other things that that the direct to the cted. So certainly exced about serv that market with an turned our transs? Er system and think the comination of those two things continue to dri senting we we have irly high conversion now within vascular surgeions use our Trans Su? Er system. We we that were some around 20% of the overall procedures by vascular surgeions or sum exc about offering in opt with in the community for guard as well that we drive every COUR sentend solion of court C guard being the best available option. So to have that that opportunity TR the C guard priv ard the development re tract re think about we we, we the the Ion and and development part the process and were now one to the regatory L suing things remain on TR time rel to what we spoke about. four to be IST but were now to and to the regulatory pro case which certainly ability 20 C more expected ation, the pect percent 20 question have fir the ation roll ment over llly senting is H the other options we we COUR to begining the process of maing C guard available. Like said to the 20 it we we actually arded, sent in the GUARD trial two and rollars the F and then actually take two CIT that COUR C Guard and converted of those back. Well the opportunity to have a discussion. C guard for both of those options available to pations TR? ment. Thanks for the the questionions prog. Thank's the courveragethe CL question and's turn the conferens ment TR ING mar perat one for taing the call and ongoing COUR. We ingly pri of the progress from this courarter and the first half of the year and 4: two the courarterly upd no M and our continue progress. The concl conference call con nine Thank pro Ping and have present.